View Item 

Show simple item record

Development and Validation of the Pediatric Charcot–Marie–Tooth Disease Quality of Life Outcome Measure
dc.contributor.authorRamchandren, Sindhu
dc.contributor.authorWu, Tong Tong
dc.contributor.authorFinkel, Richard S.
dc.contributor.authorSiskind, Carly E.
dc.contributor.authorFeely, Shawna M. E.
dc.contributor.authorBurns, Joshua
dc.contributor.authorReilly, Mary M.
dc.contributor.authorEstilow, Timothy
dc.contributor.authorShy, Michael E.
dc.date.accessioned2021-02-04T21:53:22Z
dc.date.available2022-03-04 16:53:21en
dc.date.available2021-02-04T21:53:22Z
dc.date.issued2021-02
dc.identifier.citationRamchandren, Sindhu; Wu, Tong Tong; Finkel, Richard S.; Siskind, Carly E.; Feely, Shawna M. E.; Burns, Joshua; Reilly, Mary M.; Estilow, Timothy; Shy, Michael E. (2021). "Development and Validation of the Pediatric Charcot–Marie–Tooth Disease Quality of Life Outcome Measure." Annals of Neurology 89(2): 369-379.
dc.identifier.issn0364-5134
dc.identifier.issn1531-8249
dc.identifier.urihttps://hdl.handle.net/2027.42/166254
dc.publisherJohn Wiley & Sons, Inc.
dc.titleDevelopment and Validation of the Pediatric Charcot–Marie–Tooth Disease Quality of Life Outcome Measure
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPsychiatry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166254/1/ana25966_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166254/2/ana25966.pdf
dc.identifier.doi10.1002/ana.25966
dc.identifier.doihttps://dx.doi.org/10.7302/177
dc.identifier.sourceAnnals of Neurology
dc.identifier.citedreferenceWare JE Jr, Sherbourne CD. The MOS 36‐item Short‐Form Health Survey (SF‐36): I. Conceptual framework and item selection. Med Care 1992; 30: 473 – 483.
dc.identifier.citedreferenceLandgraf JM, Abetz L, Ware JE. The Child Health Questionnaire (CHQ) user’s manual. 2nd ed. Boston, MA: HealthAct, 1999.
dc.identifier.citedreferenceWaters E, Salmon L, Wake M, et al. The Child Health Questionnaire in Australia: reliability, validity and population means. Aust N Z J Public Health 2000; 24: 207 – 210.
dc.identifier.citedreferenceRentz AM, Matza LS, Secnik K, et al. Psychometric validation of the Child Health Questionnaire (CHQ) in a sample of children and adolescents with attention‐deficit/hyperactivity disorder. Qual Life Res 2005; 14: 719 – 734.
dc.identifier.citedreferenceArnold A, McEntagart M, Younger DS. Psychosocial issues that face patients with Charcot‐Marie‐Tooth disease: the role of genetic counseling. J Genet Couns 2005; 14: 307 – 318.
dc.identifier.citedreferencePadua L, Aprile I, Cavallaro T, et al. Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study. Neurol Sci 2006; 27: 417 – 423.
dc.identifier.citedreferencePadua L, Pareyson D, Aprile I, et al. Natural history of CMT1A including QoL: a 2‐year prospective study. Neuromuscul Disord 2008; 18: 199 – 203.
dc.identifier.citedreferenceRedmond AC, Burns J, Ouvrier RA. Factors that influence health‐related quality of life in Australian adults with Charcot‐Marie‐Tooth disease. Neuromuscul Disord 2008; 18: 619 – 625.
dc.identifier.citedreferenceVarni JW, Seid M, Kurtin PS. The PedsQL™ 4.0: reliability and validity of the Pediatric Quality of Life Inventory™ version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39: 800 – 812.
dc.identifier.citedreferenceVarni JW, Limbers CA. The Pediatric Quality of Life Inventory: measuring pediatric health‐related quality of life from the perspective of children and their parents. Pediatr Clin North Am 2009; 56: 843 – 863.
dc.identifier.citedreferenceVogels T, Verrips GH, Verloove‐Vanhorick SP, et al. Measuring health‐related quality of life in children: the development of the TACQOL parent form. Qual Life Res 1998; 7: 457 – 465.
dc.identifier.citedreferenceMcHorney CA, Ware JE Jr, Raczek AE. The MOS 36‐item Short‐Form Health Survey (SF‐36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247 – 263.
dc.identifier.citedreferenceWare JE, Kosinski M, Keller SK. SF‐36® physical and mental health summary scales: a User’s manual. Boston, MA: The Health Institute, 1994.
dc.identifier.citedreferenceBurns J, Ramchandren S, Ryan MM, et al. Determinants of reduced health‐related quality of life in pediatric inherited neuropathies. Neurology 2010; 75: 726 – 731.
dc.identifier.citedreferenceBoentert M, Dziewas R, Heidbreder A, et al. Fatigue, reduced sleep quality and restless legs syndrome in Charcot‐Marie‐Tooth disease: a web‐based survey. J Neurol 2010; 257: 646 – 652.
dc.identifier.citedreferenceKaiser H. An index of factorial simplicity. Psychometrika 1974; 39: 31 – 36.
dc.identifier.citedreferenceJohnson NE, Heatwole C, Creigh P, et al. The Charcot‐Marie‐Tooth Health Index: evaluation of a patient‐reported outcome. Ann Neurol 2018; 84: 225 – 233.
dc.identifier.citedreferenceEichinger K, Burns J, Cornett K, et al. The Charcot‐Marie‐Tooth functional outcome measure (CMT‐FOM). Neurology 2018; 91: e1381 – e1384.
dc.identifier.citedreferenceZhao HT, Damle S, Ikeda‐Lee K, et al. PMP22 antisense oligonucleotides reverse Charcot‐Marie‐Tooth disease type 1A features in rodent models. J Clin Invest 2018; 128: 359 – 368.
dc.identifier.citedreferenceKagiava A, Richter J, Tryfonos C, et al. Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. Hum Mol Genet 2019; 28: 3528 – 3542.
dc.identifier.citedreferenceSchiza N, Georgiou E, Kagiava A, et al. Gene replacement therapy in a model of Charcot‐Marie‐Tooth 4C neuropathy. Brain 2019; 142: 1227 – 1241.
dc.identifier.citedreferenceCampbell A. Subjective measures of well‐being. Am Psychol 1976; 31: 117 – 124.
dc.identifier.citedreferenceSkre H. Genetic and clinical aspects of Charcot‐Marie‐Tooth disease. Clin Genet 1974; 6: 98 – 118.
dc.identifier.citedreferencePassage E, Norreel JC, Noack‐Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot‐Marie‐Tooth disease. Nat Med 2004; 10: 396 – 401.
dc.identifier.citedreferenceKhajavi M, Shiga K, Wiszniewski W, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler‐J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007; 81: 438 – 453.
dc.identifier.citedreferenceMeyer zu Horste G, Prukop T, Liebetanz D, et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007; 61: 61 – 72.
dc.identifier.citedreferenceBurns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot‐Marie‐Tooth disease type 1A in children: a randomised, double‐blind, placebo‐controlled, safety and efficacy trial. Lancet Neurol 2009; 8: 537 – 544.
dc.identifier.citedreferencePareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT TRAUK): a double‐blind randomized trial. Lancet Neurol 2011; 10: 320 – 328.
dc.identifier.citedreferenceLewis RA, McDermott MP, Herrmann DN, et al. High‐dosage ascorbic acid treatment in Charcot‐Marie‐Tooth disease type 1A: results of a randomized, double‐masked, controlled trial. JAMA Neurol 2013; 70: 981 – 987.
dc.identifier.citedreferenceFridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the inherited neuropathies consortium natural history study: a cross sectional analysis. J Neurol Neurosurg Psychiatry 2015; 86: 873 – 878.
dc.identifier.citedreferenceRamchandren S, Shy M, Feldman E, et al. Defining disability: development and validation of a mobility‐disability severity index (mDSI) in Charcot‐Marie‐Tooth disease. J Neurol Neurosurg Psychiatry 2015; 86: 635 – 639.
dc.identifier.citedreferenceBurns J, Ouvrier R, Estilow T, et al. Validation of the Charcot‐Marie‐Tooth Disease Pediatric Scale as an outcome measure of disability. Ann Neurol 2012; 71: 642 – 652.
dc.identifier.citedreferenceSadjadi R, Reilly MM, Shy ME, et al. Psychometrics evaluation of Charcot‐Marie‐Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis. J Peripher Nerv Syst 2014; 19: 192 – 196.
dc.identifier.citedreferenceFridman V, Sillau S, Acsadi G, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology 2020; 94: e884 – e896.
dc.identifier.citedreferenceOuvrier R, Geevasingha N, Ryan MM. Autosomal‐recessive and X‐linked forms of hereditary motor and sensory neuropathy in childhood. Muscle Nerve 2007; 36: 131 – 143.
dc.identifier.citedreferenceNicholson GA, Magdelaine C, Zhu D, et al. Severe early‐onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations. Neurology 2008; 70: 1678 – 1681.
dc.identifier.citedreferenceJani‐Acsadi A, Ounpuu S, Pierz K, Acsadi G. Pediatric Charcot‐Marie‐Tooth disease. Pediatr Clin North Am 2015; 62: 767 – 786.
dc.identifier.citedreferenceEstilow T, Glanzman AM, Burns J, et al. Balance impairment in pediatric Charcot‐Marie‐Tooth disease. Muscle Nerve 2019; 60: 242 – 249.
dc.identifier.citedreferenceRamchandren S, Shy ME, Finkel RS. Quality of life in children with CMT type1A. Lancet Neurol 2009; 8: 880 – 881.
dc.identifier.citedreferenceBurns J, Ryan MM, Ouvrier RA. Quality of life in children with Charcot‐Marie‐Tooth disease. J Child Neurol 2010; 25: 343 – 347.
dc.identifier.citedreferenceJuniper EF, Guyatt GH, Feeny DH, et al. Minimum skills required by children to complete health‐related quality of life instruments for asthma: comparison of measurement properties. Eur Respir J 1997; 10: 2285 – 2294.
dc.identifier.citedreferencePatrick DL, Erickson P. Health status and health policy. Oxford, UK: Oxford University Press, 1993.
dc.identifier.citedreferenceRamchandren S, Leonard M, Mody R, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 2009; 14: 184 – 189.
dc.identifier.citedreferencePatrick DL, Burke LB, Powers JH, et al. Patient‐reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10: S125 – S137.
dc.identifier.citedreferenceUS Food and Drug Administration. Guidance for industry. Patient‐reported outcome measures: use in medical product development to support labeling claims. Docket no. 2006‐D−0362. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed May 7, 2020.
dc.identifier.citedreferenceLai JS, Nowinski C, Victorson D, et al. Quality‐of‐life measures in children with neurological conditions: pediatric Neuro‐QOL. Neurorehabil Neural Repair 2012; 26: 36 – 47.
dc.identifier.citedreferenceReilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot‐Marie‐Tooth disease (CMT). Neuromuscul Disord 2010; 20: 839 – 846.
dc.identifier.citedreferenceLandgraf J, Maunsell E, Speechley K, et al. Canadian‐French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. Qual Life Res 1998; 7: 433 – 445.
dc.working.doi10.7302/177en
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ana25966_am.pdf
Size:
879.0KB
Format:
PDF
View/Open
Name:
ana25966.pdf
Size:
325.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.